A Future Of Medicine

<p>Support this podcast! <a href="https://anchor.fm/chubbyemu/support">https://anchor.fm/chubbyemu/support</a></p> <p>Video version of this video: <a href="https://youtu.be/iVt5BpoTHYg">https://youtu.be/iVt5BpoTHYg</a></p> <p>Tweet me: <a href="https://twitter.com/HemeReview">https://twitter.com/HemeReview</a></p> <p>IG me: <a href="https://instagram.com/HemeReview">https://instagram.com/HemeReview</a></p> <p>Music by Lifeformed: <a href="http://lifeformed.bandcamp.com/">http://lifeformed.bandcamp.com/</a></p> <p>References:</p> <p>[0] Chapman PB et. al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.Ann Oncol. 2017 Oct 1;28(10):2581-2587. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28961848">https://www.ncbi.nlm.nih.gov/pubmed/28961848</a></p> <p>[1] Chapman PB. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 2011; 364:2507-2516. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1103782">https://www.nejm.org/doi/full/10.1056/NEJMoa1103782</a></p> <p>[2] Amy Harmon. New Drugs Stir Debate on Rules of Clinical Trials. New York Times, September 19, 2010. <a href="https://www.nytimes.com/2010/09/19/health/research/19trial.html">https://www.nytimes.com/2010/09/19/health/research/19trial.html</a></p>